{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:25:52Z","timestamp":1787689552643,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Anti-M\u00fcllerian hormone (AMH) is now considered the best serum biomarker of ovarian reserve, while basal sex hormones are classic markers used for assessing ovarian reserve. The interaction between AMH and sex hormones are complicated and not sufficiently addressed. In this study, we took diminished ovarian reserve (DOR) and polycystic ovarian syndrome (PCOS) as two extremes of ovarian reserve (deficient and excessive respectively) to investigate the role of AMH and sex hormones in follicular growth.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective cross-sectional survey was performed. The patients assessed AMH and basal sex hormones in the Second Hospital of Zhejiang University from April 2016 to March 2019 were involved in this study. Serum AMH and sex hormone concentrations were tested with electrochemiluminescence method. Stepwise linear regression and binary logistic regression was used to determine the predictors of AMH level and to explore the involved factors determining DOR and PCOS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the present study, we found that age and follicle-stimulating hormone (FSH) were main negative correlation factors, and luteinizing hormone (LH) and testosterone (T) were main positive factors of AMH. In DOR group, age, FSH and estradiol (E<jats:sub>2<\/jats:sub>) increased and T decreased, while in PCOS group, LH and T increased. Binary logistic regression found that age, weight, FSH, E<jats:sub>2<\/jats:sub>, and T were the significant factors which independently predicted the likelihood of DOR, and that age, body mass index (BMI), AMH, LH, and T predicted the likelihood of PCOS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our study demonstrated that age, FSH, and T were factors that most closely correlated with AMH level, and T was involved in both DOR and PCOS. Since DOR and PCOS are manifested with insufficient AMH and excessive AMH respectively, it is suggested that total testosterone correlated with AMH closely and plays an important role in follicular growth. More attention should be given to testosterone level during controlled ovarian hyperstimulation (COH) process.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12902-020-00569-6","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T11:03:54Z","timestamp":1594206234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Role of anti-M\u00fcllerian hormone and testosterone in follicular growth: a cross-sectional study"],"prefix":"10.1186","volume":"20","author":[{"given":"Ping-Ping","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Peng","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Chang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Ping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-7331","authenticated-orcid":false,"given":"Chun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"issue":"5","key":"569_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/humupd\/dmu020","volume":"20","author":"SL Broer","year":"2014","unstructured":"Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-M\u00fcllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688\u2013701.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"569_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.fertnstert.2010.04.006","volume":"95","author":"KR Hansen","year":"2011","unstructured":"Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170\u20135.","journal-title":"Fertil Steril"},{"issue":"1","key":"569_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/humrep\/dep366","volume":"25","author":"J van Disseldorp","year":"2010","unstructured":"van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010;25(1):221\u20137.","journal-title":"Hum Reprod"},{"issue":"4","key":"569_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/humrep\/deh688","volume":"20","author":"R Fanchin","year":"2005","unstructured":"Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod. 2005;20(4):923\u20137.","journal-title":"Hum Reprod"},{"issue":"5","key":"569_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/uog.10114","volume":"39","author":"S Deb","year":"2012","unstructured":"Deb S, Campbell BK, Pincott-Allen C, Clewes JS, Cumberpatch G, Raine-Fenning NJ. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-M\u00fcllerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound Obstet Gynecol. 2012;39(5):574\u201380.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"6","key":"569_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/cen.13967","volume":"90","author":"J van Helden","year":"2019","unstructured":"van Helden J, Evliyaoglu O, Weiskirchen R. Has GnRH a direct role in AMH regulation. Clin Endocrinol. 2019;90(6):827\u201333.","journal-title":"Clin Endocrinol"},{"issue":"12","key":"569_CR7","doi-asserted-by":"publisher","first-page":"E1961","DOI":"10.1210\/jc.2013-2410","volume":"98","author":"HI Su","year":"2013","unstructured":"Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women. J Clin Endocrinol Metab. 2013;98(12):E1961\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"569_CR8","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1071\/RD17377","volume":"30","author":"O Kereilwe","year":"2018","unstructured":"Kereilwe O, Pandey K, Borromeo V, Kadokawa H. Anti-M\u00fcllerian hormone receptor type 2 is expressed in gonadotrophs of postpubertal heifers to control gonadotrophin secretion. Reprod Fertil Dev. 2018;30(9):1192\u2013203.","journal-title":"Reprod Fertil Dev"},{"issue":"16","key":"569_CR9","doi-asserted-by":"publisher","first-page":"9348","DOI":"10.1073\/pnas.1633592100","volume":"100","author":"GY B\u00e9d\u00e9carrats","year":"2003","unstructured":"B\u00e9d\u00e9carrats GY, O'Neill FH, Norwitz ER, Kaiser UB, Teixeira J. Regulation of gonadotropin gene expression by Mullerian inhibiting substance. Proc Natl Acad Sci U S A. 2003;100(16):9348\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"569_CR10","doi-asserted-by":"publisher","first-page":"10055","DOI":"10.1038\/ncomms10055","volume":"7","author":"I Cimino","year":"2016","unstructured":"Cimino I, Casoni F, Liu X, et al. Novel role for anti-M\u00fcllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055.","journal-title":"Nat Commun"},{"issue":"5","key":"569_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1530\/rep.0.1240601","volume":"124","author":"AL Durlinger","year":"2002","unstructured":"Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-M\u00fcllerian hormone. Reproduction. 2002;124(5):601\u20139.","journal-title":"Reproduction."},{"issue":"6","key":"569_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/humupd\/dmw027","volume":"22","author":"D Dewailly","year":"2016","unstructured":"Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-M\u00fcllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 2016;22(6):709\u201324.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"569_CR13","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.fertnstert.2011.08.015","volume":"96","author":"L Pellatt","year":"2011","unstructured":"Pellatt L, Rice S, Dilaver N, et al. Anti-M\u00fcllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril. 2011;96(5):1246\u201351.e1.","journal-title":"Fertil Steril"},{"issue":"7","key":"569_CR14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1016\/j.fertnstert.2010.04.067","volume":"94","author":"N Gleicher","year":"2010","unstructured":"Gleicher N, Weghofer A, Barad DH. Anti-M\u00fcllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril. 2010;94(7):2824\u20137.","journal-title":"Fertil Steril"},{"issue":"4","key":"569_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ajo.12366","volume":"55","author":"K Tremellen","year":"2015","unstructured":"Tremellen K, Zander-Fox D. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan. Aust N Z J Obstet Gynaecol. 2015;55(4):384\u20139.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"3","key":"569_CR16","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.fertnstert.2014.12.093","volume":"103","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2015","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9\u2013e17..","journal-title":"Fertil Steril"},{"issue":"1","key":"569_CR17","first-page":"2","volume":"53","author":"group Csooagegage","year":"2018","unstructured":"group Csooagegage. Chinese guidelines for diagnosis and treatment of polycystic ovary syndrome. Chinese J Obstetr Gynecol. 2018;53(1):2\u20136.","journal-title":"Chinese J Obstetr Gynecol"},{"issue":"3","key":"569_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.fertnstert.2013.12.032","volume":"101","author":"Female age-related fertility decline","year":"2014","unstructured":"Female age-related fertility decline. Committee Opinion. Fertil Steril. 2014;101(3):633\u20134.","journal-title":"Fertil Steril"},{"issue":"5","key":"569_CR19","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/humrep\/den482","volume":"24","author":"M Hudecova","year":"2009","unstructured":"Hudecova M, Holte J, Olovsson M, Sundstr\u00f6m PI. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hum Reprod. 2009;24(5):1176\u201383.","journal-title":"Hum Reprod"},{"issue":"5","key":"569_CR20","first-page":"263","volume":"13","author":"K Beltadze","year":"2015","unstructured":"Beltadze K, Barbakadze L. Ovarian reserve in women of late reproductive age by the method of treatment of PCOS. Iran J Reprod Med. 2015;13(5):263\u20138.","journal-title":"Iran J Reprod Med"},{"issue":"8","key":"569_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.steroids.2013.04.005","volume":"78","author":"MI Hsu","year":"2013","unstructured":"Hsu MI. Changes in the PCOS phenotype with age. Steroids. 2013;78(8):761\u20136.","journal-title":"Steroids."},{"issue":"7","key":"569_CR22","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1210\/jc.2010-2959","volume":"96","author":"J Schmidt","year":"2011","unstructured":"Schmidt J, Br\u00e4nnstr\u00f6m M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011;96(7):2178\u201385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"569_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1530\/REP-09-0415","volume":"139","author":"L Pellatt","year":"2010","unstructured":"Pellatt L, Rice S, Mason HD. Anti-M\u00fcllerian hormone and polycystic ovary syndrome: a mountain too high. Reproduction. 2010;139(5):825\u201333.","journal-title":"Reproduction."},{"issue":"12","key":"569_CR24","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1210\/jc.2003-030727","volume":"88","author":"P Pigny","year":"2003","unstructured":"Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88(12):5957\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"569_CR25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/humrep\/des460","volume":"28","author":"A Pierre","year":"2013","unstructured":"Pierre A, Peign\u00e9 M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-M\u00fcllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod. 2013;28(3):762\u20139.","journal-title":"Hum Reprod"},{"issue":"4","key":"569_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/humrep\/det015","volume":"28","author":"R Homburg","year":"2013","unstructured":"Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28(4):1077\u201383.","journal-title":"Hum Reprod"},{"key":"569_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09513590.2018.1559807","volume":"35","author":"H Sova","year":"2019","unstructured":"Sova H, Unkila-Kallio L, Tiitinen A, et al. Hormone profiling, including anti-M\u00fcllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. Gynecol Endocrinol. 2019;35:1\u20136.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"569_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rbmo.2016.04.007","volume":"33","author":"D Garg","year":"2016","unstructured":"Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod BioMed Online. 2016;33(1):15\u201328.","journal-title":"Reprod BioMed Online"},{"issue":"1","key":"569_CR29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/jc.2006-1582","volume":"92","author":"L Pellatt","year":"2007","unstructured":"Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-M\u00fcllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92(1):240\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"569_CR30","doi-asserted-by":"publisher","first-page":"59.e1","DOI":"10.1016\/j.ajog.2014.02.026","volume":"211","author":"R Tal","year":"2014","unstructured":"Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antim\u00fcllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(1):59.e1\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"569_CR31","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1172\/JCI2081","volume":"101","author":"KA Vendola","year":"1998","unstructured":"Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998;101(12):2622\u20139.","journal-title":"J Clin Invest"},{"issue":"8","key":"569_CR32","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1210\/jcem.84.8.5929","volume":"84","author":"S Weil","year":"1999","unstructured":"Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab. 1999;84(8):2951\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5 Suppl","key":"569_CR33","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.fertnstert.2007.03.066","volume":"89","author":"MP Grossman","year":"2008","unstructured":"Grossman MP, Nakajima ST, Fallat ME, Siow Y. M\u00fcllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril. 2008;89(5 Suppl):1364\u201370.","journal-title":"Fertil Steril"},{"issue":"3","key":"569_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/cen.13269","volume":"86","author":"SL Jacob","year":"2017","unstructured":"Jacob SL, Field HP, Calder N, Picton HM, Balen AH, Barth JH. Anti-M\u00fcllerian hormone reflects the severity of polycystic ovary syndrome. Clin Endocrinol. 2017;86(3):395\u2013400.","journal-title":"Clin Endocrinol"},{"issue":"8","key":"569_CR35","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/humrep\/dex239","volume":"32","author":"A Fraissinet","year":"2017","unstructured":"Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D. Use of the serum anti-M\u00fcllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017;32(8):1716\u201322.","journal-title":"Hum Reprod"},{"issue":"12","key":"569_CR36","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/molehr\/gat065","volume":"19","author":"M Lebbe","year":"2013","unstructured":"Lebbe M, Woodruff TK. Involvement of androgens in ovarian health and disease. Mol Hum Reprod. 2013;19(12):828\u201337. https:\/\/doi.org\/10.1093\/molehr\/gat065.","journal-title":"Mol Hum Reprod"},{"issue":"4","key":"569_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/s0015-0282(16)44296-2","volume":"32","author":"LJ Rodriguez-Rigau","year":"1979","unstructured":"Rodriguez-Rigau LJ, Smith KD, Tcholakian RK, Steinberger E. Effect of prednisone on plasma testosterone levels and on duration of phases of the menstrual cycle in hyperandrogenic women. Fertil Steril. 1979;32(4):408\u201313. https:\/\/doi.org\/10.1016\/s0015-0282(16)44296-2.","journal-title":"Fertil Steril"},{"issue":"3","key":"569_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/s0015-0282(16)58525-2","volume":"66","author":"EA Trott","year":"1996","unstructured":"Trott EA, Plouffe L Jr, Hansen K, Hines R, Brann DW, Mahesh VB. Ovulation induction in clomiphene-resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase. Fertil Steril. 1996;66(3):484\u20136. https:\/\/doi.org\/10.1016\/s0015-0282(16)58525-2.","journal-title":"Fertil Steril"},{"issue":"8","key":"569_CR39","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.fertnstert.2011.04.083","volume":"95","author":"SK Sunkara","year":"2011","unstructured":"Sunkara SK, Coomarasamy A. Androgen pretreatment in poor responders undergoing controlled ovarian stimulation and in vitro fertilization treatment. Fertil Steril. 2011;95(8):e73\u20134; author reply e75. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.04.083.","journal-title":"Fertil Steril"},{"issue":"1","key":"569_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgyn.2016.01.002","volume":"46","author":"JC Qin","year":"2017","unstructured":"Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. J Gynecol Obstet Hum Reprod. 2017;46(1):1\u20137. https:\/\/doi.org\/10.1016\/j.jgyn.2016.01.002.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"3","key":"569_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/humrep\/der464","volume":"27","author":"SK Sunkara","year":"2012","unstructured":"Sunkara SK, Coomarasamy A, Arlt W, Bhattacharya S. Should androgen supplementation be used for poor ovarian response in IVF. Hum Reprod. 2012;27(3):637\u201340. https:\/\/doi.org\/10.1093\/humrep\/der464.","journal-title":"Hum Reprod"},{"issue":"7","key":"569_CR42","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/humrep\/der092","volume":"26","author":"AP Ferraretti","year":"2011","unstructured":"Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of \u2018poor response\u2019 to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616\u201324. https:\/\/doi.org\/10.1093\/humrep\/der092.","journal-title":"Hum Reprod"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-020-00569-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T23:18:26Z","timestamp":1625699906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-020-00569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s12902-020-00569-6","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"18 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (IR2019001059). Because this was a retrospectively observational study with no intervention, formal ethical approval and written consent were not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}